Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neurocrine Biosciences (NBIX)
:NBIX
Holding NBIX?
Track your performance easily
Earnings Data
Report Date
Feb 11, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
1.62Last Year’s EPS
1.44Same Quarter Last Year
Strong Buy
Based on 20 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 05, 2018
|% Change Since: 22.14%
|Next Earnings Date:Jul 31, 2018
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with strong sales figures for INGREZZA and significant progress in pipeline development. While some challenges were noted, particularly in terms of competition and program discontinuations, the strategic initiatives like the share repurchase plan and sales force expansion reflect confidence in future growth.Company Guidance
In the third quarter earnings call, Neurocrine Biosciences provided robust guidance for their future, focusing on several key metrics. The company reported $613 million in Q3 sales for INGREZZA, showing a 25% year-over-year growth and prompting an increased full-year guidance to $2.3 billion to $2.32 billion. Neurocrine outlined a four-pillar strategy to drive revenue growth, emphasizing substantial investment in INGREZZA and the upcoming launch of Crinecerfont, which is expected to become a blockbuster drug. Additionally, the Board authorized a $300 million share repurchase plan to capitalize on what they perceive as an undervaluation of the company's enterprise value. The R&D budget is expected to increase to the low to mid-30% range of revenue next year, supporting Phase III programs for NBI-845 and NBI-568, targeting major depressive disorder and schizophrenia. The company also highlighted the potential of the neuroscience-focused pipeline as a significant value driver, with several molecules poised for clinical trials, ensuring continued growth and shareholder value creation.Record Sales for INGREZZA
INGREZZA achieved $613 million in Q3 sales, reflecting a 25% year-over-year growth, with full-year guidance raised to $2.3 billion to $2.32 billion.
Robust Pipeline Progress
Proof-of-concept data obtained for two out of three novel psychiatry Phase II programs, exceeding internal expectations and derisking assets and associated biology.
Share Repurchase Plan
A $300 million share repurchase plan was announced, indicating confidence in the company's valuation.
Expanded Sales Force
Psychiatry and long-term care sales force expansion completed, expected to benefit future sales.
Crinecerfont Regulatory Progress
Regulatory activities for Crinecerfont remain on track with potential approvals by year-end.
---
NBIX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NBIX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 30, 2024 | $116.19 | $124.33 | +7.01% |
| Aug 01, 2024 | $141.57 | $153.15 | +8.18% |
| May 01, 2024 | $137.54 | $143.03 | +3.99% |
| Feb 07, 2024 | $142.96 | $136.29 | -4.67% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Neurocrine Biosciences (NBIX) report earnings?
Neurocrine Biosciences (NBIX) is schdueled to report earning on Feb 11, 2025, TBA Not Confirmed.
What is Neurocrine Biosciences (NBIX) earnings time?
Neurocrine Biosciences (NBIX) earnings time is at Feb 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NBIX EPS forecast?
NBIX EPS forecast for the fiscal quarter 2024 (Q4) is 1.62.
---